Ben-Ari, Yehezkel http://orcid.org/0000-0001-6208-8480
Funding for this research was provided by:
Neurochlore
Article History
Received: 18 December 2020
Accepted: 9 February 2021
First Online: 16 February 2021
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: Yehezkel Ben-Ari is the CEO and a shareholder of Neurochlore, a biotech company dedicated to the development of treatments for children with autism.